Article

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials

2022-12-22

Abstract excerpt

<h4>Background: </h4> Many immuno-oncology (IO) trials are conducted without biomarker selection. We performed a meta-analysis of phase I/II clinical trials evaluating immune checkpoint inhibitors (ICIs) to determine the association between biomarkers and clinical outcomes, if any. Methods We searched PubMed for phase I/II clinical trials of drugs approved by the Food and Drug Administration (labeled, off-label,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c3c14f0c-d720-5fb5-b706-70409968816a
DOI: 10.21203/rs.3.rs-2386222/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology TrialsDOI 10.21203/rs.3.rs-2386222/v1Read

Large-Scale Meta-Analysis of Potential Biomarkers for Treatment Response to Anti-PD-1/PD-L1 Immune Checkpoint InhibitorsSemantic proximity Read

Advances and prospects of biomarkers for immune checkpoint inhibitorsSemantic proximity Read

Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysisSemantic proximity Read

Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsSemantic proximity Read

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patientsSemantic proximity Read

Construction and evaluation of clinical prediction model for immunotherapy-related adverse events and clinical benefit in cancer patients receiving immune checkpoint inhibitors based on serum cytokine levelsSemantic proximity Read

Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.Semantic proximity Read

Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.Semantic proximity Read

Lessons learned from a decade of immune checkpoint inhibition: The good, the bad, and the uglySemantic proximity Read

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursSemantic proximity Read

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneitySemantic proximity Read